U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386743) titled 'A Phase III Study of GS101 Injection to Dupixent(R)' on Jan. 26.
Brief Summary: This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent(R) in participants with moderate-to-severe atopic dermatitis. A total of 572 subjects are planned to be included and randomized at a ratio of 1:1 to receive GS101 injection or Dupixent(R)
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
DRUG: GS101 injection
300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg g...